The differential and potentially more limited side effect profile of PI3Kδ inhibition compared to pan-PI3K inhibition [7, 10] may provide a therapeutic window to simultaneously target both the Ras-Erk and PI3K-Akt pathways in the treatment of JMML. Here, PIK3CD is linked to juvenile myelomonocytic leukemia.